4.5 Article

Therapeutic strategies for human poxvirus infections: Monkeypox (mpox), smallpox, molluscipox, and orf

期刊

出版社

ELSEVIER SCI LTD
DOI: 10.1016/j.tmaid.2022.102528

关键词

Monkeypox(mpox); Smallpox; Cidofovir; Brincidofovir; Tecovirimat

向作者/读者索取更多资源

Therapeutic and vaccine development for human poxvirus infections have been neglected since the eradication of smallpox in 1980. However, a recent outbreak of monkeypox has highlighted the urgent need for effective antiviral agents and vaccines. This review discusses potential therapeutic options and strategies for managing human poxvirus infections worldwide, including tecovirimat, brincidofovir, cidofovir, vaccines, and intravenous vaccinia immune globulin.
Therapeutic and vaccine development for human poxvirus infections (e.g., monkeypox (mpox) virus, variola virus, molluscum contagiosum virus, orf virus) has been largely deserted, especially after the eradication of smallpox by 1980. Human mpox is a self-limited disease confined to Central and West Africa for decades. However, since April 2022, mpox has quickly emerged as a multi-country outbreak, urgently calling for effective antiviral agents and vaccines to control mpox. Here, this review highlights possible therapeutic options (e.g., tecovirimat, brincidofovir, cidofovir) and other strategies (e.g., vaccines, intravenous vaccinia immune globulin) for the management of human poxvirus infections worldwide.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据